From: physiciansweekly.com For early-stage invasive breast cancer, involved or close pathological margins after breast-conserving surgery are associated with an increased risk for distant and local recurrence, according to a review published online Sept. 21 in The BMJ. James R. Bundred, from the University of Leeds in the United Kingdom, and colleagues conducted a systematic review and meta-analysis of literature to …
Breast-Conserving Surgery Safe for Deeply Seated Breast Cancer
By: Deborah L. Ungerleider, MD From: medscape.com The study covered in this summary was published on ResearchSquare.com as a preprint and has not yet been peer reviewed. Key Takeaways When performing breast-conserving surgery, the retroglandular approach via incision in the inframammary fold for excision of a retroglandular tumor is feasible and safe. This incision gives better cosmetic results while allowing …
Hypofractionated RT: A Potential New Standard Treatment for Certain Breast Cancers
By: Leah Lawrence From: cancertherapyadvisor.com A new study suggested that moderately hypofractionated whole-breast irradiation was safe and effective, and could be recommended as a standard therapy for breast-only radiotherapy in women who undergo breast-conserving surgery for node-negative early breast cancer. The study randomly assigned 1854 women to receive radiotherapy at either 50 Gy in 25 fractions or the hypofractionated rate …
Breast cancer recurrence after lumpectomy & RT is treatable with localized RT without mastectomy
Source: NRG Oncology From: eurekalert.org NRG Oncology trial shows that breast cancer recurrence after lumpectomy and radiation is treatable with localized radiation without mastectomy Approximately 10% of breast cancer patients treated with lumpectomy (breast-conserving surgery [BCS]) and whole-breast radiation (WBI) will have a subsequent in-breast local recurrence of cancer (IBTR) when followed long term. The surgical standard of care has …
Lumicell Completes Enrollment of Phase C Feasibility Trial for Breast Cancer Surgical Guidance Solution
From: biospace.com Lumicell, Inc., an innovation leader in image guided cancer surgery, today announced that it has completed enrollment in its Phase C feasibility clinical trial of the Lumicell Imaging System for breast cancer. With results from the Phase C feasibility trial expected in late 2019, Lumicell expects to begin the pivotal trial by the end of 2019 before applying …
Local Surgeon Reports Positive Findings from Use of 3D Marker in Breast Cancer Treatment
Better Cosmetic Outcomes and Shorter Radiation Therapy Seen in Study Results A research study by local surgical oncologist Michael Cross, M.D., F.A.C.S., concluded that use of the BioZorb® surgical marker appears to provide better cosmetic outcomes and may be associated with an increased use of breast-conserving surgery in his practice. The study found that more than 90% of patients who …